Cimzia (certolizumab pegol) / UCB, Ferring, Astellas  >>  Phase 3
Welcome,         Profile    Billing    Logout  

11 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cimzia (certolizumab pegol) / Astellas, UCB
2013-000337-13: Prediction of response to Certolizumab Pegol treatment with MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in Rheumatoid Arthritis (PreCePRA) Vorhersage des Ansprechens von Certolizumab Pegol mittels Bildgebung des Gehirns. Eine multicenter, randomisierte doppel-blind Studie. Vorhersage des Ansprechens von Certolizumab-Pegol in der Rheumatoiden Arthritis (PreCePra)

Ongoing
3
156
Europe
Cimzia, Suspension for injection in pre-filled syringe, Cimzia
Universitätsklinikum Erlangen, UCB Pharma SA
Patients with active Rheumatoid Artrhitis (DAS28 > 3.2) despite DMARD therapy Patienten mit einer aktiver Rheumatoiden Arthritis (DAS28 > 3.2) trotz Therapie mit DMARD, s, RA patients DMARD -IR RA Patienten DMARD-Versager, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2007-003239-21: A phase IIIb, open label, randomized, exploratory clinical study exploring efficacy, safety and patients’ satisfaction with Certolizumab pegol treatment in moderate to severe Crohn’s disease when treatment is administered in two different settings : either at hospital or at home

Ongoing
3
150
Europe
Certolizumab pegol, CDP870,
UCB PHARMA S.A.
Crohn\'s disease
 
 
2020-001899-14: An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunosuppressive medication can be tapered without recurrence of symptoms

Not yet recruiting
3
270
Europe
Prednisolone p.o., Sulfasalazine, Leflunomide, Methotrexate p.o., Methotrexate s.c., Etanercept, Adalimumab, Infliximab, Abatacept s.c., Abatacept i.v., Tablet, Coated tablet, , Solution for injection, Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Solution for injection in dose-dispenser cartridge, Prolonged-release tablet, Xeljanz 5/10mg Filmtabletten, Otezla Filmtabletten, Simponi 50mg Injektionslösung Vorgefüllter Injektor/Fertigspritze, Cimzia 200mg Injektionslösung in einem Fertigpen, Orencia Injektionslösung in einer Fertigspritze, Orencia 250mg Pulver, Cosentyx 150mg Injektionslösung in einer Fertigspritze, Taltz, Cimzia 200mg Injektionslösung in einer Fertigspritze, Cimzia 200mg Injektionslösung in einer Patrone für ein Dosiergerät, Orencia 125mg Injektionslösung im Fertigpen, Cosentyx 150mg Injektionslösung in einem Fertigpen, Stelara 45mg/90mg Injektionslösung, Xeljanz 11mg Retardtablette, Rinvoq 15 mg Retardtablette, Tremfya 100mg Injektionslösung, Skyrizi 75/150mg Injektionslösung
Universitätsklinikum Erlangen, Universitätsklinikum Erlangen
Psoriatic arthritis Psoriasisarthritis, Psoriatic arthritis Gelenkbeteiligung bei Schuppenflechte, Diseases [C] - Immune System Diseases [C20]
 
 
2021-005309-28: Effectiveness of certolizumab in women with unexplained recurrent implantation failure Efficacité du certolizumab chez les femmes présentant un échec d'implantation à répétition inexpliqué

Ongoing
3
161
Europe
CIMZIA 200 mg, Solution for injection in pre-filled syringe, CIMZIA® 200 mg
Assistance Publique des Hôpitaux de Paris, DGOS
Adult women with recurrent implantation failures Femmes adultes présentant des échecs d'implantation récurrents, correct immunological abnormalities and increase the pregnancy rate corriger les anomalies immunologiques et augmenter le taux de grossesse, Body processes [G] - Reproductive physiologi cal processes [G08]
 
 
SYBRA, NCT05379322: The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients

Withdrawn
3
145
RoW
Anti-TNF, Adalimumab, etanercept, certolizumab, or golimumab, JAK inhibitor, Tofacitinib, baricitinib, or upadacitinib
Abu Dhabi Stem Cells Center
Rheumatoid Arthritis
10/23
04/24
NCT01550003: Pediatric Arthritis Study of Certolizumab Pegol

Checkmark For juvenile idiopathic arthritis
Dec 2016 - Dec 2016: For juvenile idiopathic arthritis
Completed
3
193
Canada, US, RoW
Certolizumab Pegol (CZP), Cimzia
UCB BIOSCIENCES GmbH, PRA Health Sciences
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
04/24
04/24
2009-018027-33: Pediatric Arthritis Study of Certolizumab pegol

Not yet recruiting
3
193
RoW, Canada, US
Solution for injection, Cimzia
UCB BIOSCIENCES GmbH, UCB Biosciences GmbH
Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis, Diseases [C] - Immune System Diseases [C20]
 
 
CIMcare, NCT04123795: A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)

Recruiting
3
150
Canada, US
Certolizumab pegol, Placebo
UCB Biopharma SRL
Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
09/29
08/34
NCT04610476: Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Recruiting
3
270
Europe
Prednisolone, Prednisolone generic drugs, Sulfasalazine, Azulfidine, Leflunomide, Arava, Methotrexate, Lantarel, Metex, Tofacitinib, Xeljanz, Apremilast, Otezla, Etanercept, Enbrel, Erelzi, Benepali, Adalimumab, Humira, Amgevita, Imraldi, Hyrimoz, Infliximab, Remicade, Zessly, Inflectra, Certolizumab pegol, Cimzia, Golimumab, Simponi, Abatacept, Orencia, Secukinumab, Cosentyx, Ixekizumab, Taltz, Ustekinumab, Stelara
University of Erlangen-Nürnberg Medical School
Psoriatic Arthritis, Withdrawal, Reduction
10/24
10/25
NCT03414502: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting
3
400
US
Methotrexate, Methotrexate (MTX), Abatacept, Orencia, Adalimumab, Humira, Azathioprine, Imuran, Baricitinib, Olimuant, Certolizumab, Cimzia, Etanercept, Enbrel, Golimumab, Simponi, Hydroxychloroquine, Plaquenil, Infliximab, Remicade, Leflunomide, Arava, Minocycline, Minocin, Rituximab, Rituxin, Sarilumab, Kevzara, Sulfasalazine, Azulfidine, Tofacitinib, Xeljanz
University of Nebraska
Rheumatoid Arthritis
03/27
03/28
CERTIFY, NCT05930613 / 2021-005309-28: Certolizumab in Recurrent Implantation Failure (RIF)

Recruiting
3
161
Europe
Certolizumab (CIMZIA® ; TNF-α antagonist), Placebo (NaCl 0.9 % solution)
Assistance Publique - Hôpitaux de Paris, DGOS
Recurrent Unexplained Implantation Failure
04/29
04/29

Download Options